Bryon D. Johnson, PhD

Professor, Pediatrics (Hematology/Oncology/BMT) and Microbiology & Immunology

Locations

Microbiology & Immunology

Contact Information

General Interests

Cancer immunology and immunotherapy

Education

PhD, Immunology, University of Health Sciences/The Chicago Medical School (now Rosalind Franklin University), 1989
BS, Microbiology, Iowa State University, 1983

Research Interests

I am interested in understanding the biology and immunology of cancer, and uncovering novel immune-based approaches to treat cancer. My current research focuses on combining the following approaches to improve the use of cancer immunotherapy for treating both solid tumors and hematologic cancers: (1) immune checkpoint protein blockade, (2) adoptive transfer of cancer-reactive T lymphocytes, and (3) the use of metabolic inhibitors to increase T cell immunity.

Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.

(Badar T, Johnson BD, Hamadani M.) Bone Marrow Transplant. 2021 Mar;56(3):683-685 PMID: 32782349 SCOPUS ID: 2-s2.0-85089247553 08/13/2020
STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.

(Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, Johnson BD, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2021 Feb 04;12(1):41-58 PMID: 33548597 SCOPUS ID: 2-s2.0-85104314508 02/07/2021
Irradiation of the kidneys causes pathologic remodeling in the nontargeted heart: A role for the immune system.

(Lenarczyk M, Laiakis EC, Mattson DL, Johnson BD, Kronenberg A, North PE, Komorowski R, Mäder M, Baker JE.) FASEB Bioadv. 2020 Dec;2(12):705-719 PMID: 33336158 PMCID: PMC7734425 12/19/2020
Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.

(Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 11;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020
Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia.

(Shah NN, Jerkins JH, Johnson BD, Hari P.) JCO Oncol Pract. 2020 09;16(9):613-614 PMID: 32603254 SCOPUS ID: 2-s2.0-85090870606 07/01/2020
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.

(Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P.) Blood Adv. 2020 05 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020
An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.

(Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A.) J Clin Apher. 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019
Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.

(Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q.) Blood Adv. 2019 10 22;3(20):3099-3110 PMID: 31648333 PMCID: PMC6849959 SCOPUS ID: 2-s2.0-85074935557 10/28/2019
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

(D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A.) Biol Blood Marrow Transplant. 2019 08;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.

(Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB.) J Immunother Cancer. 2019 04 29;7(1):115 PMID: 31036082 PMCID: PMC6489306 SCOPUS ID: 2-s2.0-85065258266 05/01/2019
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies.

(Shah NN, Maatman T, Hari P, Johnson B.) Front Oncol. 2019;9:146 PMID: 30915277 PMCID: PMC6423158 SCOPUS ID: 2-s2.0-85063343499 03/28/2019

Bryon D. Johnson, PhD